-
Part 1 | Session 2 View from the Thoraxcenter: What's Hot at ESC 25?
-
Part 2 | Session 1 Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
Part 2 | Session 2 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
Part 2 | Session 3 Day 2 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
Part 2 | Session 4 Day 1 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
Part 3 | Session 1 VICTOR: Vericiguat in Heart Failure
-
Part 3 | Session 2 DIGIT-HF: Cardiac Glycosides in HFrEF
-
Part 3 | Session 3 BETAMI-DANBLOCK: Beta-blockers after MI
-
Part 3 | Session 4 ESC 25 Guidelines Discussion: Management of Dyslipidaemias
-
Part 3 | Session 5 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
-
Part 4 | Session 1 TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
-
Part 4 | Session 2 The VICTOR & VICTORIA Pooled Analysis
-
Part 4 | Session 4 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism
-
Part 4 | Session 6 STEEER-AF Cluster Randomised Trial by the ESC and EHRA
-
Part 4 | Session 7 NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency
-
Part 4 | Session 9 SWEDEPAD 1 and 2: Drug-Coated Devices in Peripheral Arterial Disease
-
Part 4 | Session 10 Lifetime Benefits of Combination Therapy in HFpEF
-
Part 4 | Session 11 REBOOT-CNIC: Beta-blockers After Infarction with LVEF Greater Than 40%
-
Part 4 | Session 12 ODYSSEY-HCM: Mavacamten in Non-obstructive Hypertrophic Cardiomyopathy
-
Part 4 | Session 13 Pooled MACE Data for Obicetrapib
-
Part 4 | Session 14 STRIDE: Outcomes by Sex
-
Part 4 | Session 15 The SEMA-VR CardioLink-15 Trial
-
Part 4 | Session 16 The CARUSO Trial: Carotid Plaques Stabilisation and Regression with Evolocumab
-
Part 4 | Session 17 EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
Explore ESC 25 Top Trials with Insights from the Thoraxcenter!
Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at ESC 2025.
In this comprehensive ESC wrap-up, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research directions.
00:15 - DOUBLE-CHOICE
04:43 - VANTAGE
07:44 - VICTOR and VICTORIA
11:29 - DIGIT-HF
14:22 - DAPA ACT HF-TIMI 68
16:55 - BETAMI-DANBLOCK and REBOOT-CNIC
22:13 - REFINE-ICD
25:34 - OPTION-STEMI
30:40 - DUAL-ACS
33:05 - NEO-MINDSET
35:58 - TARGET-FIRST
38:54 - OUTREACH
41:50 - FIRE
42:46 - AI-Gatekeeper
45:13 - POTCAST
Dive into our coverage of ESC Congress 2025 for groundbreaking trial results and discussions with expert faculty.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- Watch our Wrap-Up series led by Dr Mirvat Alasnag summarising the key take-aways from each day of the congress.
- For clinical trial data from principal investigators, keep up with Dr Harriette Van Spall's Late-Breaker Discussion series.
- Our concise, accessible Expert Interviews will focus on the current data and it's impact on clinical practice.
- Don't miss the Highlights series to stay ahead of the curve in each field.
- In the Journal Discussions series, authors of ECR Journal explore their special focuses in depth.
More from this programme
Part 1
View from the Thoraxcenter: What's Hot at ESC 25?
Part 2
Daily Wrap Ups with Dr Mirvat Alasnag
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Faculty Biographies
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Nicolas M Van Mieghem
Medical Director
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved large bore closure devices. He works actively in expanding TAVI indications, most notably TAVI as a means to further unload the left ventricle in heart failure patients with moderate aortic stenosis (the TAVR UNLOAD trial). Prof Van Mieghem is also involved in the development and dispersion of mechanical circulatory support (MCS) devices as well as transcatheter mitral…
Comments